Table 4.

PHQ-9 Results in the PROMISE Trial.

	CTA (N=2982)	Functional (N=3003)	P-value*
PHQ-9 (% with moderate-severe depression, score ≥15)
Baseline
Number of patients	2899	2895
Patients with moderate to severe depression (%)	19.2%	18.2%	0.34
6 month
Number of patients	2669	2550
Patients with moderate to severe depression (%)	14.8%	13.1%	0.07
12 month
Number of patients	2585	2392
Patients with moderate to severe depression (%)	13.0%	11.5%	0.12
24 month
Number of patients	2238	2001
Patients with moderate to severe depression (%)	11.5%	10.7%	0.45
PHQ-9 Composite Score			Difference Between Anatomic and Functional (95% CI)
0 (absence of depressive symptoms) to 27 (severe depressive symptoms) scale
Baseline
Number of patients	2899	2895
Median (Q1, Q3)	4 (2, 8)	4 (1, 8)
Mean (standard deviation)	5.6 (5.2)	5.4 (5.4)
6 month
Number of patients	2669	2550
Median (Q1, Q3)	3 (1, 6)	3 (1, 6)
Mean (standard deviation)	4.3 (5.0)	4.5 (4.9)	0.1 (−0.2 to 0.3)
12 month
Number of patients	2585	2392
Median (Q1, Q3)	3 (1, 6)	2 (1, 5)
Mean (standard deviation)	4.2 (4.9)	3.9 (4.6)	0.2 (−0.0 to 0.5)
24 month
Number of patients	2238	2001
Median (Q1, Q3)	2 (0, 5)	2 (0, 5)
Mean (standard deviation)	3.8 (4.7)	3.7 (4.5)	0.1 (−0.2 to 0.4)

CTA=computed tomography angiography

P-values were calculated from the chi-square test.

Diagnostic testing strategy groups are as randomized.

95% confidence intervals on treatment differences calculated as CTA minus functional testing.